Conditions: Relapsed/Refractory Leukemias; Acute Lymphoblastic Leukemia; Acute Lymphocytic Leukemia; Mixed Phenotype Acute Leukemia; Acute Myeloid Leukemia
Interventions: Drug: SNDX-5613; Drug: Chemotherapy Regimen 1; Drug: Chemotherapy Regimen 2
Sponsor: Syndax Pharmaceuticals
**RECRUITING NOW**
Interventions: Drug: SNDX-5613; Drug: Chemotherapy Regimen 1; Drug: Chemotherapy Regimen 2
Sponsor: Syndax Pharmaceuticals
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
